

# Anita K Dunbier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9393999/publications.pdf>

Version: 2024-02-01

37  
papers

3,631  
citations

257101

24  
h-index

344852

36  
g-index

37  
all docs

37  
docs citations

37  
times ranked

5106  
citing authors

#	ARTICLE	IF	CITATIONS
1	Variable expression quantitative trait loci analysis of breast cancer risk variants. <i>Scientific Reports</i> , 2021, 11, 7192.	1.6	6
2	Structure vs. Function of TRIB1 in Myeloid Neoplasms and Beyond. <i>Cancers</i> , 2021, 13, 3060.	1.7	7
3	Increased gene expression variability in BRCA1-associated and basal-like breast tumours. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 363-375.	1.1	3
4	Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 95.	2.2	3
5	Substrate binding allosterically relieves autoinhibition of the pseudokinase TRIB1. <i>Science Signaling</i> , 2018, 11, .	1.6	46
6	Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers. <i>BMC Cancer</i> , 2018, 18, 805.	1.1	65
7	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , 2017, 23, 3035-3044.	3.2	28
8	Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2270-2278.	0.8	96
9	Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 35.	2.2	8
10	Aromatase Inhibitor Resistance via Non-endocrine Signalling Pathways. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 169-190.	0.1	2
11	Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers. <i>Breast Cancer Research</i> , 2014, 16, 447.	2.2	25
12	Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor-Positive Breast Cancer and Their Relationship with Antiproliferative Response. <i>Clinical Cancer Research</i> , 2014, 20, 2485-2494.	3.2	39
13	Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3962-3973.	3.2	19
14	Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. <i>Lancet Oncology</i> , The, 2013, 14, 1067-1076.	5.1	332
15	Comparison of PAM50 Risk of Recurrence Score With OncoDX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2783-2790.	0.8	557
16	Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 2775-2786.	3.2	119
17	Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R78.	2.2	38
18	New and translational perspectives of oestrogen deprivation in breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2011, 340, 137-141.	1.6	9

#	ARTICLE	IF	CITATIONS
19	Recent data on intratumor estrogens in breast cancer. <i>Steroids</i> , 2011, 76, 786-791.	0.8	28
20	Association between breast cancer subtypes and response to neoadjuvant anastrozole. <i>Steroids</i> , 2011, 76, 736-740.	0.8	48
21	ER $\pm$ -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer. <i>Cancer Discovery</i> , 2011, 1, 338-351.	7.7	284
22	Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor-Treated ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3005-3012.	3.2	31
23	Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation. <i>Clinical Cancer Research</i> , 2011, 17, 4948-4958.	3.2	58
24	A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance. <i>Clinical Cancer Research</i> , 2011, 17, 2024-2034.	3.2	88
25	Endocrine Therapy, New Biologicals, and New Study Designs for Presurgical Studies in Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 120-123.	0.9	69
26	ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1. <i>PLoS Genetics</i> , 2011, 7, e1001382.	1.5	47
27	Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor-Positive Breast Cancer in Postmenopausal Women. <i>Journal of Clinical Oncology</i> , 2010, 28, 1161-1167.	0.8	94
28	Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1829-1834.	0.8	647
29	Progress in aromatase research and identification of key future directions. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 118, 311-315.	1.2	4
30	A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: A case control study in an Italian population. <i>BMC Cancer</i> , 2008, 8, 138.	1.1	13
31	Impact of Estrogen Deprivation on Gene Expression Profiles of Normal Postmenopausal Breast Tissue <i>In vivo</i> . <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 855-863.	1.1	10
32	Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 8019-8026.	3.2	220
33	Destabilized Adhesion in the Gastric Proliferative Zone and c-Src Kinase Activation Mark the Development of Early Diffuse Gastric Cancer. <i>Cancer Research</i> , 2007, 67, 2480-2489.	0.4	114
34	N-Terminal E-Cadherin Peptides Act as Decoy Receptors for <i>Listeria monocytogenes</i> . <i>Infection and Immunity</i> , 2003, 71, 1580-1583.	1.0	19
35	Gastric Cancer: Inherited Predisposition. , 2002, , 253-258.		0
36	Hereditary diffuse gastric cancer. <i>Advances in Cancer Research</i> , 2001, 83, 55-65.	1.9	35

#	ARTICLE	IF	CITATIONS
37	Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nature Genetics, 2000, 26, 16-17.	9.4	420